The University of Chicago Header Logo

Thomas Hensing

InstitutionUniversity of Chicago
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Krantz SB, Zeeshan K, Kuchta KM, Hensing TA, Mangold KA, Zheng SL, Xu J. Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non-small cell lung cancer. JTCVS Open. 2022 Dec; 12:399-409. PMID: 36590722; PMCID: PMC9801288.
    2. Boyle CA, Ravichandran U, Hankamp V, Ilbawi N, Conway-Svec C, Shifley D, Hensing T, Kim S, Halasyamani L. Safe Transitions and Congregate Living in the Age of COVID-19: A Retrospective Cohort Study. J Hosp Med. 2021 Aug 18. PMID: 34424185.
      Citations: 1     Fields:    
    3. Hensing TA, Wang X, Stinchcombe TE, Gao J, Knopp MV, Watson M, Dudek AZ, Graziano SL, Patel JD, Faller BA, Dragnev KH, Kozono D, Vokes EE. Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clin Res Rep. 2021 Aug; 2(8):100208. PMID: 34590049; PMCID: PMC8474361.
    4. Rosenberg AJ, Rademaker A, Hochster HS, Ryan T, Hensing T, Shankaran V, Baddi L, Mahalingam D, Mulcahy MF, Benson AB. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up. Oncologist. 2019 08; 24(8):1039-e642. PMID: 31138725; PMCID: PMC6693711.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    5. Guo NL, Dowlati A, Raese RA, Dong C, Chen G, Beer DG, Shaffer J, Singh S, Bokhary U, Liu L, Howington J, Hensing T, Qian Y. A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer. EBioMedicine. 2018 Jun; 32:102-110. PMID: 29861409; PMCID: PMC6020749.
      Citations: 14     Fields:    Translation:Humans
    6. Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJ. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget. 2018 Jan 12; 9(4):4375-4384. PMID: 29435109; PMCID: PMC5796980.
      Citations: 19     Fields:    
    7. Shah S, Wood K, Brisson R, Karrison T, Hensing T, Luke JJ, Patel JD. PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S310. PMID: 27969530.
    8. Wood K, Hensing T, Salgia R. KRAS in Non-Small-Cell Lung Cancer-Reply. JAMA Oncol. 2016 10 01; 2(10):1373-1374. PMID: 27442777.
      Citations:    Fields:    Translation:Humans
    9. Campbell NP, Hensing TA, Bhayani MK, Shaikh AY, Brockstein BE. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2016 Aug; 16(8):847-58. PMID: 27400139.
      Citations: 6     Fields:    Translation:HumansCells
    10. Wood K, Hensing T, Malik R, Salgia R. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016 Jun 01; 2(6):805-12. PMID: 27100819.
      Citations: 81     Fields:    Translation:Humans
    11. Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization. Oncologist. 2016 06; 21(6):762-70. PMID: 27245569; PMCID: PMC4912370.
      Citations: 52     Fields:    Translation:Humans
    12. Vigneswaran J, Tan YH, Murgu SD, Won BM, Patton KA, Villaflor VM, Hoffman PC, Hensing T, Hogarth DK, Malik R, MacMahon H, Mueller J, Simon CA, Vigneswaran WT, Wigfield CH, Ferguson MK, Husain AN, Vokes EE, Salgia R. Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget. 2016 Apr 05; 7(14):18876-86. PMID: 26934441; PMCID: PMC4951336.
      Citations: 11     Fields:    Translation:Humans
    13. Won B, Carey GB, Tan YH, Bokhary U, Itkonen M, Szeto K, Wallace J, Campbell N, Hensing T, Salgia R. The Chicago Thoracic Oncology Database Consortium: A Multisite Database Initiative. Cureus. 2016 Mar 16; 8(3):e533. PMID: 27092293; PMCID: PMC4833499.
      Citations: 1     
    14. Dizon DS, Krilov L, Cohen E, Gangadhar T, Ganz PA, Hensing TA, Hunger S, Krishnamurthi SS, Lassman AB, Markham MJ, Mayer E, Neuss M, Pal SK, Richardson LC, Schilsky R, Schwartz GK, Spriggs DR, Villalona-Calero MA, Villani G, Masters G. Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2016 Mar 20; 34(9):987-1011. PMID: 26846975; PMCID: PMC5075244.
      Citations: 59     Fields:    Translation:Humans
    15. Rosenberg CA, Flanagan C, Brockstein B, Obel JC, Dragon LH, Merkel DE, Wade EL, Law TM, Khandekar JD, Hensing TA. Promotion of self-management for post treatment cancer survivors: evaluation of a risk-adapted visit. J Cancer Surviv. 2016 Feb; 10(1):206-19. PMID: 26178325.
      Citations: 7     Fields:    Translation:Humans
    16. Lennon FE, Cianci GC, Cipriani NA, Hensing TA, Zhang HJ, Chen CT, Murgu SD, Vokes EE, Vannier MW, Salgia R. Lung cancer-a fractal viewpoint. Nat Rev Clin Oncol. 2015 Nov; 12(11):664-75. PMID: 26169924; PMCID: PMC4989864.
      Citations: 67     Fields:    Translation:Humans
    17. Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R, Morgensztern D. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693; PMCID: PMC4346098.
      Citations: 56     Fields:    Translation:Humans
    18. Obel J, Brockstein B, Marschke M, Robicsek A, Konchak C, Sefa M, Ziomek N, Benfield T, Peterson C, Gustafson C, Eriksson J, Harper A, Tabachow C, Raymond M, Hensing T. Outpatient advance care planning for patients with metastatic cancer: a pilot quality improvement initiative. J Palliat Med. 2014 Nov; 17(11):1231-7. PMID: 25343403.
      Citations: 9     Fields:    Translation:Humans
    19. Radosevich AJ, Mutyal NN, Rogers JD, Gould B, Hensing TA, Ray D, Backman V, Roy HK. Buccal spectral markers for lung cancer risk stratification. PLoS One. 2014; 9(10):e110157. PMID: 25299667; PMCID: PMC4192585.
      Citations: 13     Fields:    Translation:Humans
    20. Somaiah N, Fidler MJ, Garrett-Mayer E, Wahlquist A, Shirai K, Buckingham L, Hensing T, Bonomi P, Simon GR. Epidermal growth factor receptor (EGFR) mutations are exceptionally rare in thyroid transcription factor (TTF-1)-negative adenocarcinomas of the lung. Oncoscience. 2014; 1(8):522-528. PMID: 25594059; PMCID: PMC4278331.
      Citations: 11     
    21. Wali RK, Hensing TA, Ray DW, Dela Cruz M, Tiwari AK, Radosevich A, Jepeal L, Fernando HC, Litle VR, Charlot M, Momi N, Backman V, Roy HK. Buccal microRNA dysregulation in lung field carcinogenesis: gender-specific implications. Int J Oncol. 2014 Sep; 45(3):1209-15. PMID: 24919547; PMCID: PMC4144027.
      Citations: 11     Fields:    Translation:Humans
    22. Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R. Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433. PMID: 24722523; PMCID: PMC4039220.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    23. Hensing T, Chawla A, Batra R, Salgia R. A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117. PMID: 24292963.
      Citations: 56     Fields:    Translation:Humans
    24. Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013 Sep 20; 31(27):3320-6. PMID: 23980091; PMCID: PMC3770864.
      Citations: 149     Fields:    Translation:HumansCTClinical Trials
    25. Hensing TA, Salgia R. Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33. PMID: 23893423.
      Citations: 13     Fields:    Translation:Humans
    26. Socinski MA, Evans T, Gettinger S, Hensing TA, VanDam Sequist L, Ireland B, Stinchcombe TE. Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013 May; 143(5 Suppl):e341S-e368S. PMID: 23649446; PMCID: PMC4694611.
      Citations: 71     Fields:    Translation:Humans
    27. Carey GB, Kazantsev S, Surati M, Rolle CE, Kanteti A, Sadiq A, Bahroos N, Raumann B, Madduri R, Dave P, Starkey A, Hensing T, Husain AN, Vokes EE, Vigneswaran W, Armato SG, Kindler HL, Salgia R. Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma. BMJ Open. 2012; 2(5). PMID: 23103606; PMCID: PMC3488720.
      Citations: 3     Fields:    
    28. Stinchcombe TE, Peterman AH, Lee CB, Moore DT, Beaumont JL, Bradford DS, Bakri K, Taylor M, Crane JM, Schwartz G, Hensing TA, McElroy E, Niell HB, Harper HD, Pal S, Socinski MA. A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age =70 years) with stage IIIB/IV non-small cell lung cancer. J Thorac Oncol. 2011 Sep; 6(9):1569-77. PMID: 21716146.
      Citations: 14     Fields:    Translation:HumansCTClinical Trials
    29. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    30. Brockstein B, Hensing T, Carro GW, Obel J, Khandekar J, Kaminer L, Van De Wege C, de Wilton Marsh R. Effect of an electronic health record on the culture of an outpatient medical oncology practice in a four-hospital integrated health care system: 5-year experience. J Oncol Pract. 2011 Jul; 7(4):e20-4. PMID: 22043197; PMCID: PMC3140456.
      Citations: 5     Fields:    
    31. Yount S, Beaumont J, Rosenbloom S, Cella D, Patel J, Hensing T, Jacobsen PB, Syrjala K, Abernethy AP. A brief symptom index for advanced lung cancer. Clin Lung Cancer. 2012 Jan; 13(1):14-23. PMID: 21729652; PMCID: PMC4486486.
      Citations: 11     Fields:    Translation:Humans
    32. Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83. PMID: 21421117.
      Citations: 19     Fields:    Translation:HumansCells
    33. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Rolle CE, Kanteti R, Ferguson BD, Hasina R, Gangadhar TC, Salama AK, Arif Q, Kirchner C, Mendonca E, Campbell N, Limvorasak S, Villaflor V, Hensing TA, Krausz T, Vokes EE, Husain AN, Ferguson MK, Karrison TG, Salgia R. Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11. PMID: 21603121; PMCID: PMC3164615.
      Citations: 8     
    34. Mollberg N, Surati M, Demchuk C, Fathi R, Salama AK, Husain AN, Hensing T, Salgia R. Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94. PMID: 21337123; PMCID: PMC3077059.
      Citations: 9     Fields:    Translation:Humans
    35. Surati M, Robinson M, Nandi S, Faoro L, Demchuk C, Kanteti R, Ferguson B, Gangadhar T, Hensing T, Hasina R, Husain A, Ferguson M, Karrison T, Salgia R. Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47). PMID: 21304468; PMCID: PMC3182654.
      Citations: 4     Fields:    Translation:Humans
    36. Roy HK, Hensing T, Backman V. Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. Future Oncol. 2011 Jan; 7(1):1-3. PMID: 21174531; PMCID: PMC4123752.
      Citations: 10     Fields:    Translation:Humans
    37. Roy HK, Subramanian H, Damania D, Hensing TA, Rom WN, Pass HI, Ray D, Rogers JD, Bogojevic A, Shah M, Kuzniar T, Pradhan P, Backman V. Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010 Oct 15; 70(20):7748-54. PMID: 20924114; PMCID: PMC3703950.
      Citations: 35     Fields:    Translation:HumansPHPublic Health
    38. Stinchcombe TE, Bradford DS, Hensing TA, LaRocca RV, Saleh M, Evans T, Bakri K, Socinski MA. A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15. PMID: 19916742.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    39. Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53. PMID: 20007525.
      Citations: 58     Fields:    Translation:Humans
    40. Subramanian H, Roy HK, Pradhan P, Goldberg MJ, Muldoon J, Brand RE, Sturgis C, Hensing T, Ray D, Bogojevic A, Mohammed J, Chang JS, Backman V. Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res. 2009 Jul 01; 69(13):5357-63. PMID: 19549915; PMCID: PMC2802178.
      Citations: 82     Fields:    Translation:Humans
    41. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9. PMID: 19433684.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    42. Hensing TA, Subramanian H, Roy HK, Breault D, Bogojevic Z, Ray D, Hasabou N, Backman V. Identification of malignancy-associated change in buccal mucosa with partial wave spectroscopy (PWS): A potential biomarker for lung cancer risk. J Clin Oncol. 2008 May 20; 26(15_suppl):11045. PMID: 27947658.
    43. Patel JD, Hensing TA, Rademaker F, Hart E, Obasaju CK, Treat J, Milton D, Bonomi PD. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8044. PMID: 27949033.
    44. Stinchcombe TE, Harper HD, Hensing TA, Moore DT, Crane JM, Atkins JN, Willard EM, Detterbeck FC, Socinski MA. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51. PMID: 18303435.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    45. Lilenbaum RC, Cashy J, Hensing TA, Young S, Cella D. Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008 Feb; 3(2):125-9. PMID: 18303431.
      Citations: 71     Fields:    Translation:Humans
    46. Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8. PMID: 18282359.
      Citations: 5     Fields:    Translation:Humans
    47. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, Socinski MA. Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53. PMID: 17805063.
      Citations: 41     Fields:    Translation:Humans
    48. Davis K, Yount S, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton D, Masters G, Hensing T, Cella D. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7. PMID: 17944147.
      Citations: 13     Fields:    Translation:Humans
    49. Cella D, Wagner L, Cashy J, Hensing TA, Yount S, Lilenbaum RC. Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr. 2007; (37):53-60. PMID: 17951232.
      Citations: 8     Fields:    Translation:Humans
    50. Hensing TA, Hanna NH, Gillenwater HH, Gabriella Camboni M, Allievi C, Socinski MA. Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704. PMID: 16917215.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    51. Govindan R, Natale R, Wade J, Herbst R, Krebs A, Reiling R, Hensing T, Wozniak A, Belani CP, Kelly K, Ochs J. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7. PMID: 16797779.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    52. Hoang T, Kim K, Merchant J, Traynor AM, McGovern J, Oettel KR, Sanchez FA, Ahuja HG, Hensing TA, Larson M, Schiller JH. Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25. PMID: 17409860.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    53. Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60. PMID: 17409827.
      Citations: 6     Fields:    Translation:Humans
    54. Socinski MA, Ivanova A, Bakri K, Wall J, Baggstrom MQ, Hensing TA, Mears A, Tynan M, Beaumont J, Peterman AH, Niell HB. A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9. PMID: 16249215.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    55. Reiling RB, Natale R, Wade J, Herbst R, Hensing T, Belani CP, Kelly K, Ochs J, Govindan R, Wozniak A, Krebs A. Efficacy and safety of gefitinib in chemo-naive patients with non-small cell lung cancer (NSCLC) in an expanded access program (EAP). J Clin Oncol. 2005 Jun; 23(16_suppl):7094. PMID: 27944554.
    56. Collichio F, Ollila D, Huck K, Mullen N, Shearer H, Turner E, Kelly H, Zeger E, Socinski M, Hensing T. A phase II trial of weekly 1-hour paclitaxel in stage IV melanoma. J Clin Oncol. 2005 Jun; 23(16_suppl):7565. PMID: 27946033.
    57. Hensing TA. Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):219-35, v. PMID: 15833404.
      Citations: 4     Fields:    Translation:Humans
    58. Gillenwater HH, Stinchcombe TE, Qaqish BF, Tyann M, Hensing TA, Socinski MA. A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9. PMID: 15713525.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    59. Hensing TA, Schell MJ, Lee JH, Socinski MA. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9. PMID: 15639724.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    60. Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, Hensing TA, Socinski MA. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004 Dec 01; 22(23):4837-45. PMID: 15570087.
      Citations: 91     Fields:    Translation:Humans
    61. Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 01; 22(21):4341-50. PMID: 15514375.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    62. Stitzenberg KB, Groben PA, Stern SL, Thomas NE, Hensing TA, Sansbury LB, Ollila DW. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004 Oct; 11(10):900-6. PMID: 15383424.
      Citations: 13     Fields:    Translation:Humans
    63. Hensing TA, Peterman AH, Schell MJ, Lee JH, Socinski MA. The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88. PMID: 12910523.
      Citations: 30     Fields:    Translation:HumansCTClinical Trials
    64. Socinski MA, Baggstrom MQ, Hensing TA. Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8. PMID: 16227958.
      Citations: 1     Fields:    Translation:Humans
    65. Kwock L, Smith JK, Castillo M, Ewend MG, Cush S, Hensing T, Varia M, Morris D, Bouldin TW. Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat. 2002 Feb; 1(1):17-28. PMID: 12614173.
      Citations: 13     Fields:    Translation:Humans
    66. Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA, Ewend MG, Carey LA, Morris DE, Harvey RD, Hensing TA. Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47. PMID: 12057099.
      Citations: 7     Fields:    Translation:Humans
    67. Hensing TA, Detterbeck F, Socinski MA. The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control. 2000 Jan-Feb; 7(1):45-55. PMID: 10740660.
      Citations:    Fields:    Translation:Humans
    68. Hensing TA, Socinski MA. Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med. 1999 Jul; 5(4):194-200. PMID: 10407686.
      Citations:    Fields:    Translation:Humans
    Hensing's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (229)
    Co-Authors (30)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors